Researchers at NSHA who played a key role in getting a new drug approved in Canada for polycystic kidney disease are taking part in a national follow-up study of the drug’s long-term effects.
While the number of patients waiting for a kidney transplant has risen by 400 per cent over the past 25 years, the number of kidney donors has risen by only four per cent.
At any given time, the Division of Nephrology is involved in half a dozen clinical trials to test and/or validate new approaches to managing the many issues that arise with dialysis and kidney disease.
Although colon cancer is not in the spotlight like breast and prostate cancer, it is the second-most common cancer in Nova Scotia in both women and men. And, rates are higher in Atlantic Canada than the rest of the country.
If fatty liver disease is diagnosed early enough—before it progresses to the inflammatory stage that accelerates scarring and leads to cirrhosis—it can be halted and even reversed with weight loss and lifestyle changes.
Researchers at NSHA are working hard to systematically identify and remove barriers that prevent people with IBD from gaining access to timely, high-quality care.
